Dr Upveja discusses a prospective, multicentre study evaluating the cost and logistical implications of intravenous (IV) versus subcutaneous (SC) trastuzumab (TZM) in 747 Moroccan patients with HER2-positive breast cancer.

While SC administration was associated with shorter hospital visits (163 vs 220 minutes), the total direct cost per treatment was significantly higher than IV (6258 vs 4087 Moroccan Dirham).

Despite SC's logistical advantages, IV TZM proved to be more cost-effective with comparable clinical utility, suggesting it as the more economically viable option in Morocco’s healthcare setting.